S A Riddler

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Acquir Immune Defic Syndr 48:281-8. 2008
  2. ncbi Class-sparing regimens for initial treatment of HIV-1 infection
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, USA
    N Engl J Med 358:2095-106. 2008
  3. ncbi A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Antivir Ther 12:531-41. 2007
  4. ncbi Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy
    S A Riddler
    University of Pittsburgh, Pittsburgh, PA, USA
    HIV Med 8:280-7. 2007
  5. ncbi Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens
    C R Rinaldo
    Deptartment of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA
    J Infect Dis 179:329-36. 1999
  6. ncbi Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency
    C R Rinaldo
    Graduate School of Public Health, Pittsburgh, Pennsylvania 15261, USA
    J Virol 74:4127-38. 2000
  7. ncbi Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches
    Nancy C Connolly
    University of Pittsburgh, Pittsburgh, PA 15213, USA
    AIDS Rev 7:168-80. 2005
  8. ncbi Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115
    Allan R Tenorio
    Department of Medicine, Rush Medical College, Rush University Medical Center, 600 S Paulina Street, Chicago, IL 60612, USA
    AIDS Res Hum Retroviruses 25:135-9. 2009
  9. ncbi Impact of HIV infection and HAART on serum lipids in men
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, PA, USA
    JAMA 289:2978-82. 2003
  10. ncbi Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity
    Sharon A Riddler
    University of Pittsburgh, Pennsylvania, USA
    Antimicrob Agents Chemother 46:3877-82. 2002

Detail Information

Publications24

  1. ncbi Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA
    J Acquir Immune Defic Syndr 48:281-8. 2008
    ..Alterations in serum lipids and an increased risk of myocardial infarction have been associated with HIV-1 infection and its treatment...
  2. ncbi Class-sparing regimens for initial treatment of HIV-1 infection
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, USA
    N Engl J Med 358:2095-106. 2008
    ..The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs...
  3. ncbi A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115
    Sharon A Riddler
    Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
    Antivir Ther 12:531-41. 2007
    ..Clinical stability has been observed with continued antiretroviral therapy (ART) in the setting of partial virological suppression. The optimal time to switch treatment in patients with low but detectable HIV-1 RNA is not known...
  4. ncbi Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy
    S A Riddler
    University of Pittsburgh, Pittsburgh, PA, USA
    HIV Med 8:280-7. 2007
    ..The aim of the study was to describe longitudinal changes in serum lipids among HIV-infected men receiving highly active antiretroviral therapy (HAART) with long-term follow-up...
  5. ncbi Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens
    C R Rinaldo
    Deptartment of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15261, USA
    J Infect Dis 179:329-36. 1999
    ..Prolonged indinavir-zidovudine-lamivudine treatment has significant but incomplete enhancing effects on CD4 T cell reactivity, which could be important in host control of microbial and persistent HIV-1 infections...
  6. ncbi Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency
    C R Rinaldo
    Graduate School of Public Health, Pittsburgh, Pennsylvania 15261, USA
    J Virol 74:4127-38. 2000
    ..These results indicate that new strategies will be needed to target residual, immunocompetent HIV-1-specific CD8(+) T cells to enhance the effectiveness of antiretroviral therapy in patients with advanced immunodeficiency...
  7. ncbi Proinflammatory cytokines in HIV disease-a review and rationale for new therapeutic approaches
    Nancy C Connolly
    University of Pittsburgh, Pittsburgh, PA 15213, USA
    AIDS Rev 7:168-80. 2005
    ..This review presents what is known about the dysregulation of proinflammatory cytokines in HIV-1 infection, highlighting newly available immune-based therapies that could augment antiretroviral drug therapies...
  8. ncbi Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115
    Allan R Tenorio
    Department of Medicine, Rush Medical College, Rush University Medical Center, 600 S Paulina Street, Chicago, IL 60612, USA
    AIDS Res Hum Retroviruses 25:135-9. 2009
    ..Delaying a treatment switch in patients with partial virologic suppression and stable CD4+ T cells does not have profound effects on immune parameters...
  9. ncbi Impact of HIV infection and HAART on serum lipids in men
    Sharon A Riddler
    University of Pittsburgh, Pittsburgh, PA, USA
    JAMA 289:2978-82. 2003
    ....
  10. ncbi Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity
    Sharon A Riddler
    University of Pittsburgh, Pennsylvania, USA
    Antimicrob Agents Chemother 46:3877-82. 2002
    ..The combination of IDV and NFV was generally well tolerated and resulted in sustained virologic suppression with 45% of the subjects having an HIV-1 RNA level in plasma of <400 copies/ml at week 72 (intent-to-treat)...
  11. ncbi Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals
    Nancy C Connolly
    Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Clin Vaccine Immunol 15:284-92. 2008
    ..DC vaccination was safe, was feasible, and showed promise of immunogenicity in ART-treated, HIV-1-positive individuals. Additional studies of DC immunization strategies for HIV-1 infection are warranted...
  12. ncbi In vitro and in vivo protein sampling by combined microdialysis and ultrafiltration
    A J Rosenbloom
    Carnegie Mellon University, Molecular Biosensors and Imaging Center MBIC and Institute for Complex Engineered Systems ICES, Department of Critical Care Medicine, Pittsburgh, PA 15213, USA
    J Immunol Methods 309:55-68. 2006
    ..This technology, combined with a multiplexed immunoassay, facilitates the simultaneous measurement of cytokines and chemokines in response to injury in the oral mucosa of human subjects in vivo...
  13. ncbi Production of a dendritic cell-based vaccine containing inactivated autologous virus for therapy of patients with chronic human immunodeficiency virus type 1 infection
    Theresa L Whiteside
    Department of Pathology, University of Pittsburgh School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15213 1863, USA
    Clin Vaccine Immunol 16:233-40. 2009
    ..bb-ind-13137)...
  14. ncbi Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study
    Todd T Brown
    Department of Medicine, School of Medicine, The Johns Hopkins University, Baltimore, MD, USA
    Arch Intern Med 165:1179-84. 2005
    ..The risk of diabetes mellitus (DM) in human immunodeficiency virus (HIV)-infected patients receiving highly active antiretroviral therapy (HAART) has not been well defined...
  15. ncbi Prevalence of chlamydia and gonorrhoea among a population of men who have sex with men
    R L Cook
    University of Pittsburgh, PA 15213, USA
    Sex Transm Infect 78:190-3. 2002
    ....
  16. ncbi Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study
    Frank J Palella
    Northwestern University, Feinberg School of Medicine, Div of Infectious Diseases, Chicago, Illinois 60611, USA
    Clin Infect Dis 38:903-7. 2004
    ....
  17. ncbi Recovery of replication-competent HIV type 1-infected circulating monocytes from individuals receiving antiretroviral therapy
    Sharon M Harrold
    Department of Pathology, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
    AIDS Res Hum Retroviruses 18:427-34. 2002
    ..These studies demonstrate that HIV-infected individuals on ART with breakthrough viremia have significantly higher levels of circulating infected monocytes, the precursors of tissue macrophages...
  18. ncbi Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy
    Stephen J Gange
    Department of Epidemiology and Molecular Microbiology and Immunology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA
    AIDS 17:119-21. 2003
  19. ncbi Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s
    Daniel R Kuritzkes
    Section of Retroviral Therapeutics, Brigham and Women s Hospital, Cambridge, MA 02139, USA
    J Infect Dis 195:1169-76. 2007
    ..We sought to compare clearance rates of plasma human immunodeficiency virus type 1 (HIV-1) RNA in men and women starting triple-nucleoside-based versus efavirenz (EFV)-based regimens...
  20. ncbi Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study
    Todd T Brown
    Johns Hopkins University, School of Medicine, Baltimore, Maryland, USA
    AIDS 19:1375-83. 2005
    ..To estimate insulin resistance and its relationship to antiretroviral therapy (ART) in a cohort of HIV-infected persons with comparison to HIV-seronegative controls...
  21. ncbi Rapid declines in total lymphocyte counts and hemoglobin concentration prior to AIDS among HIV-1-infected men
    Bryan Lau
    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    AIDS 17:2035-44. 2003
    ..These results suggest that TLC and Hgb might be useful for monitoring disease progression in resource-limited settings...
  22. ncbi Interruption and discontinuation of highly active antiretroviral therapy in the multicenter AIDS cohort study
    Xiuhong Li
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    J Acquir Immune Defic Syndr 38:320-8. 2005
    ..CONCLUSIONS: Host characteristics play a role in short interruptions, whereas longer interruptions may be clinically indicated. These longer stoppages had further virologic and immunologic consequences, however...
  23. ncbi Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003
    Eric C Seaberg
    Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland 21205, USA
    AIDS 19:953-60. 2005
    ..UO1-AI-35041: To examine the impact of HIV infection and highly active antiretroviral therapy on systolic and diastolic hypertension...
  24. ncbi Use of total lymphocyte count and hemoglobin concentration for monitoring progression of HIV infection
    Bryan Lau
    Department of Epidemiology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA
    J Acquir Immune Defic Syndr 39:620-5. 2005
    ..These results support the potential utility of these markers for monitoring HIV-infected people in resource-limited regions, but critical levels and rates of decline of markers for such regions remain to be defined...